Many studies have demonstrated that sodium–glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) significantly reduce major adverse cardiovascular events (MACE), the risk of worsening heart failure (HF), hospitalizations due to HF, arrhythmic events in patients with HF [4], and overall mortality in patients with type 2 diabetes [5,6,7]. Here, GLP1R is linked to type 2 diabetes mellitus.